Technical Articles

The development of KRAS-targeted drugs relies on a variety of biochemical and cellular analytical platforms. From the production and quality control of target proteins, to the measurement of compound binding affinity with KRAS, and the validation of signaling pathway inhibition in cells, a standardized analytical process is an essential infrastructure for new drug discovery.

Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) is a highly sensitive biophysical technique that combines time-resolved fluorescence detection with the principle of Förster resonance energy transfer.

Cyclic adenosine monophosphate, as an important second messenger molecule within cells, directly reflects the activation or inhibition state of the G protein-coupled receptor signaling pathway.

Time-resolved fluorescence resonance energy transfer is a homogeneous detection technique based on non-radiative energy transfer between fluorescent donor and acceptor molecules. The core of this technology lies in the use of lanthanide chelates as fluorescent donors, with common lanthanide elements including europium and terbium.

The KRAS gene, a member of the RAS family with the highest mutation frequency, plays a critical driving role in the occurrence and development of various malignant tumors.

Homogeneous time-resolved fluorescence technology is a novel detection platform that integrates the two core technologies of time-resolved fluorescence and fluorescence resonance energy transfer, and has wide applications in drug screening, life science research, and clinical diagnostics.

TR-FRET Technology Empowers PROTAC/Molecular Glue Research